Management of vaccinations in patients with non‐Hodgkin lymphoma
Open Access
- 26 March 2024
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1617-1634
Abstract
Summary: Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non‐Hodgkin lymphomas (NHLs). The COVID‐19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life‐threatening SARS‐CoV‐2‐related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine‐induced immune responses after anti‐CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients. In this review, we summarize the existing data about COVID‐19 and other vaccine's efficacy in patients with NHL and propose multidisciplinary team‐based recommendations for the management of vaccines in this specific group of patients.Keywords
This publication has 119 references indexed in Scilit:
- Long‐term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphomaAmerican Journal of Hematology, 2023
- Immune response to COVID‐19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapyeJHaem, 2023
- Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV‐2 booster vaccination in hematologic neoplasmsAmerican Journal of Hematology, 2023
- Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendationsHematological Oncology, 2022
- Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19JAMA Oncology, 2022
- Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignanciesCancer, 2022
- Immunogenicity and clinical efficacy of anti‐SARS‐CoV‐2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patientsAmerican Journal of Hematology, 2022
- Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virusAnnals of Hematology, 2022
- Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant DiseaseJAMA Oncology, 2021
- Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell TransplantationJAMA, 2019